English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Anticholinergic medications are the gold standard in pharmacotherapy for neurogenic bladder. The first line agent in Australia is oxybutynin due to cost and accessibility. Oxybutynin is available in both oral and transdermal forms. Oral oxybutynin can be associated with a significant side effect profile in some children. Additionally, compliance may be poor with oral medication due to difficulty in taking tablets in addition to inability to tolerate associated side effects. Transdermal formulations have the potential advantage of ease of use resulting in increased compliance and reduced systemic side effects. effects. CONCLUSIONS

MP56-16 EFFICACY AND SAFETY OF TRANSDERMAL OXYBUTYNIN VERSUS ORAL OXYBUTYNIN IN THE MANAGEMENT OF PEDIATRIC NEUROGENIC BLADDER